BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial
Everest Medicines (1952.HK) announced on Wednesday that its EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor for treatment of primary membranous nephropathy (pMN), showed positive results in its…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
